Last reviewed · How we verify
Hypnotics
Hypnotics is a Small molecule drug developed by Laval University. It is currently in Phase 1 development.
Hypnotics are a class of psychoactive drugs that induce sleep and treat insomnia, with some also used to treat conditions such as chronic pain and narcolepsy. They are typically small molecule drugs, including compounds like Lemborexant, which have been studied in clinical trials for various indications including anesthesia, chronic insomnia, and chronic pain.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hypnotics |
|---|---|
| Sponsor | Laval University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Hypnotic Communication To Reduce Anxiety And Pain During Prostate Biopsy (HYCapp) (NA)
- Evaluation of the Therapeutic Approach of Aromatherapy by Olfaction of Essential Oils in Association With Hypnosis in the Management of Patients Followed for Cancer
- Matching Adults to Treatments for Chronic Pain (MATCH) Study (NA)
- Inhaled Sedation in Critically Ill Patients (PHASE4)
- Anesthesia sTrategy foR Organ Procurement In braiN dEath (PHASE3)
- Hypnotic Communication in Cardiology: A Randomized Controlled Trial (NA)
- Prevention of Postoperative Respiratory Complications
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypnotics CI brief — competitive landscape report
- Hypnotics updates RSS · CI watch RSS
- Laval University portfolio CI
Frequently asked questions about Hypnotics
What is Hypnotics?
Who makes Hypnotics?
What development phase is Hypnotics in?
Related
- Manufacturer: Laval University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing